PriceTargets.com logo

Orchestra BioMed - OBIO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $13.60
  • Forecasted Upside: 253.25%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.85 As of 06/16/2026 05:00 PM ET
▼ -0.12 (-3.02%)

This chart shows the closing price for OBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Orchestra BioMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBIO

Analyst Price Target is $13.60
▲ +253.25% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Orchestra BioMed in the last 3 months. The average price target is $13.60, with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 253.25% upside from the last price of $3.85.

This chart shows the closing price for OBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 contributing investment analysts is to moderate buy stock in Orchestra BioMed. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/17/2026
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/16/2026

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/19/2026B. Riley FinancialLower TargetBuy ➝ Buy$12.00 ➝ $10.00
5/14/2026HC WainwrightReiterated RatingBuy ➝ Buy$10.00
5/13/2026BarclaysBoost TargetOverweight ➝ Overweight$12.00 ➝ $13.00
4/21/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
4/2/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/12/2026Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
1/9/2026BarclaysBoost TargetOverweight ➝ Overweight$11.00 ➝ $12.00
12/10/2025TD CowenInitiated CoverageBuy
12/10/2025TD CowenInitiated CoverageBuy$15.00
11/13/2025Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
11/12/2025BarclaysLower TargetOverweight ➝ Overweight$12.00 ➝ $11.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/4/2025HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $10.00
8/20/2025BTIG ResearchReiterated RatingBuy ➝ Neutral
8/13/2025Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
8/7/2025Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
5/13/2025Chardan CapitalReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/5/2025BarclaysLower TargetOverweight ➝ Overweight$16.00 ➝ $12.00
4/23/2025HC WainwrightReiterated RatingBuy ➝ Buy
4/22/2025Chardan CapitalReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/4/2025HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $12.00
4/3/2025B. Riley FinancialUpgradeStrong-Buy
4/1/2025Chardan CapitalReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/20/2025BTIG ResearchInitiated CoverageBuy$12.00
3/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
1/2/2025BarclaysInitiated CoverageOverweight$16.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
11/13/2024Chardan CapitalReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
8/22/2024HC WainwrightInitiated CoverageBuy$14.00
7/25/2024B. Riley FinancialInitiated CoverageBuy$15.00
6/12/2024Chardan CapitalReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/28/2024Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
1/19/2024Jefferies Financial GroupInitiated CoverageBuy$14.00
8/9/2023Chardan CapitalReiterated RatingBuy ➝ Buy$20.00
3/8/2023Lifesci CapitalReiterated RatingOutperform
2/24/2023Piper SandlerInitiated CoverageOverweight$15.00
2/7/2023Chardan CapitalInitiated CoverageBuy$20.00
(Data available from 6/17/2021 forward)

News Sentiment Rating

1.16 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Orchestra BioMed logo
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Read More

Today's Range

Now: $3.85
Low: $3.85
High: $4.05

50 Day Range

MA: $4.08
Low: $3.72
High: $4.58

52 Week Range

Now: $3.85
Low: $2.20
High: $5.42

Volume

478,927 shs

Average Volume

217,049 shs

Market Capitalization

$230.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Orchestra BioMed?

The following Wall Street analysts have issued stock ratings on Orchestra BioMed in the last year: B. Riley Financial, Inc., Barclays PLC, BTIG Research, Chardan Capital, HC Wainwright, TD Cowen, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for OBIO.

What is the current price target for Orchestra BioMed?

0 Wall Street analysts have set twelve-month price targets for Orchestra BioMed in the last year. Their average twelve-month price target is $13.60, suggesting a possible upside of 253.2%. Chardan Capital has the highest price target set, predicting OBIO will reach $20.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Orchestra BioMed in the next year.
View the latest price targets for OBIO.

What is the current consensus analyst rating for Orchestra BioMed?

Orchestra BioMed currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OBIO.

What other companies compete with Orchestra BioMed?

Other companies that are similar to Orchestra BioMed include Anteris Technologies Global, Alpha Tau Medical, InMode, Bioventus and CeriBell. Learn More about companies similar to Orchestra BioMed.

How do I contact Orchestra BioMed's investor relations team?

Orchestra BioMed's physical mailing address is 40 10TH AVENUE FLOOR 7, NEW YORK NY, 10014. The company's listed phone number is 646-597-6980 and its investor relations email address is [email protected]. The official website for Orchestra BioMed is orchestrabiomed.com. Learn More about contacing Orchestra BioMed investor relations.